Video

Dr. Smith Advises Clinicians on Diagnosing Double-Hit and Triplet-Hit Lymphoma

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma.

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, advises clinicians on diagnosing double-hit and triple-hit lymphoma in patients with diffuse large B-cell lymphoma (DLBCL).

Double-hit and triplet-hit lymphomas are uncommon but not rare, and needs to be looked for in patients diagnosed with DLBCL, Smith says. This subtype is enriched in patients with a germinal center phenotype, as well in those with high-risk features. Smith says that the most important thing is to take a big enough biopsy. If there is a suspicion for an aggressive B-cell lymphoma, Smith advises clinicians to take enough tissue to test for it during initial biopsy.

The most important thing to do when a patient presents with a double-hit lymphoma is to confirm the diagnosis with the pathologist, Smith says. Nuances including amplification, copy number alterations, and mutations can make a difference. Additionally, Smith says that R-CHOP is not going to be sufficient, and clinicians should consider a more intensive therapeutic regimen for these patients.

Related Videos
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic